Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
The synergy of the activities between chloroquine and various human immunodeficiency virus protease inhibitors was investigated in chloroquine-resistant and -sensitive malaria parasites. In both in vitro and in vivo assay systems, ritonavir was found to be the most potent in potentiating the antimalarial action of chloroquine.
He
Zhengxiang
Z
Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510663, China.
Qin
Li
L
Chen
Lili
L
Peng
Nanzheng
N
You
Jianlan
J
Chen
Xiaoping
X
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage*; D000069446:Atazanavir Sulfate; D002738:Chloroquine / Q000008:administration & dosage*; D004351:Drug Resistance; D004357:Drug Synergism; D005260:Female; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D006801:Humans; D066298:In Vitro Techniques; D061466:Lopinavir; D008288:Malaria / Q000188:drug therapy / Q000469:parasitology; D051379:Mice; D019888:Nelfinavir / Q000008:administration & dosage; D009842:Oligopeptides / Q000008:administration & dosage; D016788:Plasmodium chabaudi / Q000187:drug effects*; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000254:growth & development; D011725:Pyridines / Q000008:administration & dosage; D011744:Pyrimidinones / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage; D019258:Saquinavir / Q000008:administration & dosage
D000962:Antimalarials; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D002738:Chloroquine; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir